Annual Report 2021

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2021 89 The United Laboratories International Holdings Limited Annual Report 2021 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information (Continued) For the year ended 31 December 2020 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 1,840 – 10,872 – 12,712 Depreciation of right-of-use assets 4,975 2,572 759 – 8,306 Depreciation of property, plant and equipment 455,141 80,141 49,639 8,526 593,447 Net (gain) loss on disposal of property, plant and equipment (4,591) (448) 183 (38,679) (43,535) Impairment losses (reversed) recognised (4,914) (933) 2,377 69,382 65,912 (c) Geographical information The revenue by geographical market (irrespective of the origin of the goods) based on the location of the customers are presented below: Revenue from external customers 2021 2020 RMB’000 RMB’000 PRC, including Hong Kong (country of domicile) 7,607,485 6,259,058 Europe 530,715 730,289 India 688,842 818,938 Middle East 27,844 58,040 South America 234,769 227,875 Other Asian regions 480,380 421,103 Other regions 133,403 257,185 9,703,438 8,772,488